J Natl Compr Canc Netw. 2018 Oct;16(10):1166-1170. doi: 10.6004/jnccn.2018.7056.
Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline -directed therapy eliciting a response in metastatic SDC.
涎腺导管癌（SDC）是一种罕见且侵袭性的恶性肿瘤，目前针对其治疗决策的相关数据有限。随着先进的分子检测和肿瘤基因组分析技术的出现，临床医生现在有能力在 SDC 等治疗困难的癌症中识别潜在的治疗靶点。本报告介绍了一名男性广泛转移性 SDC 患者，通过靶向下一代测序发现存在 p.V600E 突变。他对一线系统化疗（达布拉非尼联合曲美替尼）表现出了持久而显著的反应。在他的缓解期内，新的数据出现，为他的疾病进展后使用免疫检查点抑制剂和雄激素阻断治疗提供了依据。据我们所知，这是首例一线靶向治疗在转移性 SDC 中产生疗效的报告。
